treatment. Improvements in cognitive symptoms were observed during the fi rst 12 weeks, which were more pronounced in patients with rapid progression than in those with slow progression. Rapidly progressing patients experienced signifi cantly greater cognitive benefi ts than slowly progressing patients (p = 0.029), who experienced a modest decline in cognitive symptoms at the end of the study. Comment: Patients experiencing rapid symptom progression may receive greater benefi t from rivastigmine than those with slow progression. In this study, cholinesterase inhibition appeared to be of particular utility in the management of AD patients whose symptoms were rapidly worsening. 
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder, characterized by the degeneration of cholinergic neurons in the nucleus basalis, and the presence of amyloid plaques and neurofi brillary tangles [1] .
The rate of AD progression varies considerably between individuals and is believed to be infl uenced by a number of factors, including genetic (e.g., apolipoprotein E 4 polymorphism or butyrylcholinesterase-K allele), age at onset, gender, duration of illness (disease stage), and the presence or absence of extrapyramidal features [2] [3] [4] [5] [6] [7] [8] [9] . It has been shown that patients presenting with a rapid rate of cognitive decline will continue to experience clinically signifi cant symptom progression sooner than those presenting with relatively slow rates of cognitive decline [9] . Furthermore, another study demonstrated that, after adjusting for age, gender and education, mortality in AD patients was still very strongly associated with their rate of cognitive decline [10] . Therefore, AD patients experiencing more rapid progression early in the disease need particular attention as they are more likely to reach clinically signifi cant milestones earlier, have a poorer prognosis, and a higher mortality rate than those experiencing slow symptom progression. An assessment of how rapidly the illness is progressing as well as how severely the AD patient is currently affected would, therefore, be important in determining prognosis, a frequent concern of families and/or caregivers.
A recent retrospective analysis of one randomized, placebo-controlled rivastigmine study, and its open-label extension, showed that the treatment response to rivastigmine on measures of cognitive and functional performance during the open-label extension was more pronounced in AD patients experiencing rapid cognitive decline on placebo during the randomized phase than in those experiencing a slow rate of decline [11] . The results of this analysis suggested that the rate of AD progression may predict magnitude and/or likelihood of response to cholinesterase inhibitor (ChEI) treatment. The suggestion that a subset of patients may gain particular benefi ts from rivastigmine appeared to warrant further investigation. Thus, in this follow-up meta-analysis, using pooled data derived from four large, randomized placebo-controlled rivastigmine studies, we evaluated the effects of rivastigmine on the cognitive performance of AD patients previously on placebo, stratifi ed by their rates of cognitive decline during the preceding randomized phase.
Methods

Study Design and Patients
This meta-analysis utilized data from the fi rst 26 weeks of two large open-label rivastigmine (up to 12 mg daily) extension studies within the ADENA database ( fi g. 1 ). Patients entering these studies came from four randomized double-blind, placebo-controlled trials, the full methodologies and fi ndings of which have been previously published [12] [13] [14] [15] . Patients with a diagnosis of probable AD were enrolled in these randomized trials according to previously described inclusion and exclusion criteria [12] [13] [14] [15] and were randomized to rivastigmine or placebo and treated over a 26-week period.
Informed consent was obtained prior to enrollment and subsequently, after each full year of participation, for those patients remaining on treatment in each open-label extension study. These extension studies were approved by the Ethics Committee overseeing the sites and were performed in accordance with good clinical practice guidelines and the Declaration of Helsinki.
In the open-label extension studies, both investigators and patients remained masked to the patient's original treatment assignment (i.e., placebo or rivastigmine) during the double-blind phase.
Patients entering the open-label extension studies were retitrated to their highest well-tolerated rivastigmine dose, starting at 1 mg b.i.d. and rising to a maximum tolerated dose of 6 mg b.i.d. 
Cognitive Effi cacy Assessment
In the open-label extension studies, the effect of rivastigmine treatment on cognitive performance was evaluated using the Alzheimer's Disease Assessment Scale -cognitive subscale (ADAScog) [16] and the Mini-Mental State Examination [17] .
Current Meta-Analysis
This meta-analysis focused on the effects of open-label rivastigmine treatment on cognitive decline, as measured on the ADAS-cog [16] . Two groups of patients, identifi ed as those with 'rapid' or 'slow' progression during a 26-week assessment period, while receiving placebo, in the double-blind trials prior to entry into the open-label extension phase, were determined ( fi g. 1 ). Patients participating in the rivastigmine arms of the double-blind trials were not included in the two groups (rapid and slow progressors) in this meta-analysis since we hypothesized that therapy may have affected their true rates of cognitive decline over the 26 weeks prior to enrolling in the open-label extension phase. While on placebo, rapidly progressing patients were identifi ed as having experienced a 6 4-point decline in ADAS-cog scores over the previous 26 weeks, while slowly progressing patients exhibited a ! 4-point decline on the ADAS-cog scale during the initial 26-week treatment period.
The ADAS-cog [16] is currently considered the 'gold standard' for assessing changes in cognitive function in AD trials. A higher ADAS-cog score represents poorer cognitive performance, while a negative change from the baseline score with treatment refl ects an improvement. Data from ADAS-cog assessments performed at weeks 26 (i.e., start of open-label treatment phase or baseline), 38, 44 and 52 (or at early termination) of the open-label phases of these studies were analyzed.
It could be argued that rapidly progressing patients exhibit greater symptoms and the probability of showing drug effect is higher; therefore, validation of these data was critical. SAS version 8 and S-PLUS version 6.1 were used for summary statistics and modelling, respectively. Statistical comparisons between the rapidly and slowly progressing patients during the open-label phase were made by applying a longitudinal mixed-effects model to assess the change in slope of cognitive symptom progression after initiation of rivastigmine treatment. Importantly, the model adjusted for the baseline differences in cognitive impairment between the slow and rapid progressors. The difference in effect between rapidly and slowly progressing patients was assessed by deviation of the slope for the rapid progressors. In order to correct the respective p value for a possible regression to the mean effect, the data set was simulated 10,000 times from the fi tted model with no difference between rapid and slow progressors. Patients were then split into rapid and slow progression subgroups according to the predefi ned criterion, based on the simulation data. The p value derived from the empirical data was compared with the distribution of the simulated p values from the null model with no difference in treatment effect (i.e., representing pure chance fi ndings). The resultant p value was corrected for the comparison of the rivastigmine effect on the slowly progressing patients and the rapidly progressing patients. A p value of less than 0.05 was considered to be statistically significant.
Results
Patients
In total, 679 patients fi nished placebo treatment during the double-blind phases of the four rivastigmine clinical trials [12] [13] [14] and subsequently entered the open-label phases of one of two extension studies. Six hundred and seventy-two patients provided ADAS-cog data. Of these patients, 240 were 'rapidly progressing' and 432 were 'slowly progressing' while on placebo treatment (i.e., weeks 0-26). Of these, 180 (75%) rapidly progressing patients and 337 (78%) slowly progressing patients provided ADAS-cog data after 26 weeks of open-label rivastigmine treatment (i.e., weeks 26-52).
The baseline characteristics of these two groups are shown in table 1 . The rapid and slow progression subgroups had similar mean ages and durations of dementia, and comprised similar proportions of men and women. As might be expected, rapidly progressing patients had a higher ADAS-cog mean score (34.9 vs. 20.7) at baseline than the slowly progressing patients. Similarly, a greater proportion of rapidly progressing patients had baseline Global Deterioration Scale scores refl ecting moderate-severe AD relative to the slowly progressing patients (81 vs. 60%). Rapidly progressing patients reached a mean daily rivastigmine dose of 8.1 mg, and slowly progressing patients reached a mean daily dose of 7.9 mg.
Assessment of Cognitive Decline
During 26 weeks of placebo treatment in the doubleblind rivastigmine clinical trials, rapidly progressing patients experienced a worsening of cognitive functioning (mean ADAS-cog increase of 8.5). However, cognitive functioning of slowly progressing patients improved slightly during this 26-week placebo treatment period ( table 2 ).
Both those with rapid and slow progression treated with rivastigmine experienced improvements in cognitive symptoms (i.e., a negative mean change in ADAS-cog from baseline levels) during the fi rst 12 weeks of the openlabel treatment phase (weeks 26-38). However, rapidly progressing patients receiving rivastigmine experienced a greater magnitude of cognitive improvement than the slowly progressing patients (mean 8 SEM ADAS-cog change decline in ADAS-cog scores (positive mean change increase relative to baseline) from weeks 38-52, the rapidly progressing patients who remained on treatment for 26 weeks continued to experience an overall improvement in their cognitive symptoms ( fi g. 2 ). Furthermore, the improvement in ADAS-cog scores relative to baseline for the patients with rapid progression was signifi cantly greater than that for patients with slow progression (p = 0.029; fi g. 2 ).
Discussion
All AD patients remaining on open-label rivastigmine treatment for 26 weeks appeared to experience cognitive benefi ts, regardless of their prior rate of decline in cognitive functioning. In particular, improvements in cognitive symptoms were observed for patients remaining on rivastigmine treatment after the fi rst 12 weeks of the open-label phase, which were more pronounced in the previously rapidly progressive group than in the slowly progressive group. Overall, rapidly progressing patients remaining on rivastigmine treatment for 26 weeks experienced signifi cantly greater mean magnitude of cognitive benefi ts than slowly progressing patients.
Another possible explanation for the results seen in this study might be the higher ADAS-cog score of the rapidly progressing patients at the start of open-label treatment. Having considered this, the statistical model used for this meta-analysis adjusted for the baseline differences in cognitive impairment between slow and rapid progressors. Therefore, it is hoped that the infl uence of baseline cognitive differences between the subgroups will have been minimal. Nevertheless, it is plausible that the psychometric properties of the scale might have allowed the detection of larger changes for individuals who were in the middle of the scale, where maximum rates of change could have been occurring.
These results are consistent with the fi ndings of our previous retrospective analysis of a single rivastigmine trial in which we also found better preserved daily function in patients with rapid progression, as well as improved cognition [11] . To date, rivastigmine is the only ChEI to have demonstrated this differential cognitive effect in AD patients experiencing rapid cognitive deterioration relative to those with slow cognitive deterioration.
Rivastigmine inhibits butyrylcholinesterase (BuChE) in addition to acetylcholinesterase (AChE). There is increasing acceptance that BuChE has a signifi cant role in cholinergic neurotransmission in the normal brain [18] , and this role may increase with advancing severity of AD [19] . Besides its effects on cholinergic neurotransmission, rivastigmine may have broader effects in AD, for example, by affecting cerebral blood fl ow, amyloidogenesis, and tau phosphorylation [20] . BuChE levels increase in areas of the brain involved in neurodegeneration (i.e., entorhinal and inferotemporal cortex) as AD progresses, while AChE levels decrease [21] . Brain BuChE activity in the temporal cortex has also been correlated with the rate of cognitive decline in patients with dementia [22] . Furthermore, the presence of the BuChE-K variant, which has reduced enzymatic activity, appears to correlate with a slower rate of cognitive decline and preserved attentional performance in patients with AD and dementia with Lewy bodies [23, 24] . These fi ndings suggest that BuChE may play a role in disease progression and is an important target in addition to AChE in the treatment of AD, particularly in those patients with a rapid rate of cognitive deterioration.
The fi ndings of the present meta-analysis, together with our previous analysis [11] , suggest that patients experiencing rapid symptom progression may be particularly likely to benefi t from rivastigmine treatment. Whether similar responses would be seen with other ChEIs has not yet been confi rmed.
